Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT1308 plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for PD-L1-positive persistent, recurrent, or metastatic cervical cancer
CTR20232394Phase 3Active
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of BAT1308 in Cervical Cancer (CC), sponsored by Bio-Thera Solutions, Ltd.. Started Dec 2023; status: active.
02
Drugs
BAT1308
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on CTR20232394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232394.